Benedikt Huttner
Biographic Data
| ID | 9006753 |
|---|---|
| NAME | Benedikt Huttner |
| GIVEN NAMES | Benedikt |
| FAMILY NAME | Huttner |
| SIGNATURE | HUTTNER B |
| AFFILIATIONS | World Health Organization |
| ORCID | 0000-0002-1749-9464 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Reserve antibiotics
New antibiotics active against multidrug resistant bacteria (MDR-B) are licensed by regulatory agencies based on pivotal trials that serve the primary purpose of obtaining marketing-authorization. There is increasing concern that they do not offer guidance on how to best use new antibiotics, in which population, and to what extent they overcome existing resistance. We reviewed the literature for pre-approval studies (phase 2 and 3 randomized cont…
User-experience testing of an evidence-to-decision framework for selecting essential medicines
Essential medicine lists (EMLs) are important medicine prioritization tools used by the World Health Organization (WHO) EML and over 130 countries. The criteria used by WHO’s Expert Committee on the Selection and Use of Essential Medicines has parallels to the GRADE Evidence-to-Decision (EtD) frameworks. In this study, we explored the EtD frameworks and a visual abstract as adjunctive tools to strengthen the integrate evidence and improve the tra…
No prominent works on this page.
User-experience testing of an evidence-to-decision framework for selecting essential medicines
Essential medicine lists (EMLs) are important medicine prioritization tools used by the World Health Organization (WHO) EML and over 130 countries. The criteria used by WHO’s Expert Committee on the Selection and Use of Essential Medicines has parallels to the GRADE Evidence-to-Decision (EtD) frameworks. In this study, we explored the EtD frameworks and a visual abstract as adjunctive tools to strengthen the integrate evidence and improve the tra…
Reserve antibiotics
New antibiotics active against multidrug resistant bacteria (MDR-B) are licensed by regulatory agencies based on pivotal trials that serve the primary purpose of obtaining marketing-authorization. There is increasing concern that they do not offer guidance on how to best use new antibiotics, in which population, and to what extent they overcome existing resistance. We reviewed the literature for pre-approval studies (phase 2 and 3 randomized cont…
Business (2 works) · Antibiotic Resistance in Bacteria (1 work) · Antibiotic Use and Resistance (1 work) · Antibiotics Pharmacokinetics and Efficacy (1 work) · Bioinformatics (1 work) · Biology (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Clinical trial (1 work) · Computer Science (1 work) · Environmental health (1 work)